基线磁共振成像前列腺影像报告和数据系统评分与前列腺癌主动监测早期活检重新分级的关联:密歇根泌尿外科手术改进协作组(MUSIC)数据
该多中心队列研究纳入1491例接受主动监测的NCCN低危或有利中危前列腺癌男性,评估基线MRI PI-RADS评分与监测活检重新分级的关系。中位随访11.0个月,基线PI-RADS≥4病灶与活检重新分级风险升高相关(HR 2.3,95%CI 1.6-3.2,P<.001),PI-RADS评分与NCCN风险组交互作用不显著(P=.7)。
要点
- 基线MRI PI-RADS≥4病灶与主动监测早期活检重新分级风险升高相关(HR 2.3,95%CI 1.6-3.2)。
- 分级组2 vs 1(HR 2.5,95%CI 1.7-3.7)和年龄每增加10岁(HR 1.8,95%CI 1.4-2.4)也与重新分级风险升高相关。
- PI-RADS评分与NCCN风险组的交互作用不显著(P=.7)。
核心结论
- 在真实世界多中心队列中,基线MRI PI-RADS评分与接受主动监测的NCCN低危或有利中危前列腺癌男性的早期活检重新分级显著相关。
研究设计与样本
- 多中心队列研究,纳入密歇根泌尿外科手术改进协作组注册数据库(46个医院/学术/私人执业泌尿外科小组)中2016年6月至2021年1月入组主动监测的NCCN低危和有利中危前列腺癌男性,共1491例,中位年龄64岁(IQR 59-69),于诊断活检前或后6个月内接受MRI。
- 采用多变量Cox比例风险回归模型,校正病理、MRI和临床/活检因素,以诊断活检后6个月为标志时间,并纳入PI-RADS评分与NCCN分组的交互项。
主要发现
- 标志时间后中位随访11.0个月(IQR 6.0-23.0),基线PI-RADS≥4病灶与活检重新分级风险升高相关(HR 2.3,95%CI 1.6-3.2,P<.001)。
- 分级组2 vs 1与活检重新分级风险升高相关(HR 2.5,95%CI 1.7-3.7,P<.001)。
- 年龄每增加10岁与活检重新分级风险升高相关(HR 1.8,95%CI 1.4-2.4,P<.001)。
- PI-RADS评分与NCCN风险组的交互作用不显著(P=.7)。
关键数值与推荐
- 基线MRI PI-RADS≥4病灶与活检重新分级至高级别前列腺癌(≥分级组3)的HR为2.3(95%CI 1.6-3.2,P<.001)。
- 分级组2 vs 1的HR为2.5(95%CI 1.7-3.7,P<.001)。
- 年龄每增加10岁的HR为1.8(95%CI 1.4-2.4,P<.001)。
- PI-RADS评分与NCCN风险组交互作用P=.7。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of our study was to evaluate the association of baseline MRI Prostate Imaging Reporting and Data System (PI-RADS) score with biopsy reclassification in a multicenter active surveillance (AS) cohort. MATERIALS AND METHODS: We identified men in the Michigan Urological Surgery Improvement Collaborative registry (46 hospital-based/academic/private practice urology groups) with National Comprehensive Cancer Network (NCCN) low-risk and favorable intermediate-risk prostate cancer who underwent MRI within 6 months before or after initial biopsy and enrolled in AS from June 2016 to January 2021. The primary objective was to determine the association of baseline MRI PI-RADS score (≥4 lesion) with reclassification to high-grade prostate cancer (≥grade group 3) on surveillance biopsy. Multivariable Cox proportional hazards regression models were constructed and adjusted for pathologic, MRI, and clinical/biopsy factors, with landmark time of 6 months from diagnostic biopsy. We included an interaction term between PI-RADS score and NCCN group in the Cox model. RESULTS: A total of 1491 men were included with median age 64 years (IQR: 59-69) with median follow-up 11.0 months (IQR: 6.0-23.0) after landmark. Baseline PI-RADS ≥ 4 lesion was associated with an increased hazard of biopsy reclassification (HR: 2.3 [95% CI: 1.6-3.2], P < .001), along with grade group 2 vs 1 (HR: 2.5 [95% CI: 1.7-3.7], P < .001), and increasing age (per 10 years; HR: 1.8 [95% CI: 1.4-2.4], P < .001). The interaction between NCCN risk group with MRI findings was not significant (P = .7). CONCLUSIONS: In this multicenter cohort study of real-world data, baseline MRI PI-RADS score was significantly associated with early biopsy reclassification in men undergoing AS with NCCN low- or favorable intermediate-risk prostate cancer.
引用
- Nandalur KR, Shen C, Zhao L, et al. Association of Baseline Magnetic Resonance Imaging Prostate Imaging Reporting and Data System Score With Prostate Cancer Active Surveillance Early Biopsy Reclassification: Data From the Michigan Urological Surgery Improvement Collaborative (MUSIC). J Urol. 2024. PMID: 38917450. doi:10.1097/JU.0000000000004117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。